Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.23
-0.0650-5.02%
Post-market: 1.230.00000.00%16:47 EDT
Volume:46.39K
Turnover:57.33K
Market Cap:3.77M
PE:-0.17
High:1.29
Open:1.29
Low:1.21
Close:1.30
Loading ...

BRIEF-Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas

Reuters
·
26 Mar

Sonnet Biotherapeutics Successfully Completes First Safety Review of Son-1010 in Combination With Trabectedin in Certain Sarcomas

THOMSON REUTERS
·
26 Mar

Sonnet Biotherapeutics Holdings : Safety Review Committee Found No Unexpected Toxicities in Early Dosing of Son-1010 in First 7 Patients at Mtd

THOMSON REUTERS
·
26 Mar

Sonnet Biotherapeutics : Annual Review Showed Extended Safety of Son-1010 Monotherapy at Mtd With Clinical Benefit in 83% of Patients at That Dose

THOMSON REUTERS
·
26 Mar

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

GlobeNewswire
·
26 Mar

Sonnet BioTherapeutics receives notice of allowance for U.S. patent for IL-18

TIPRANKS
·
19 Mar

Sonnet Biotherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of Its Il-18 Binding Protein Resistant Variant Protein

THOMSON REUTERS
·
19 Mar

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

GlobeNewswire
·
19 Mar

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire
·
11 Mar

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

GlobeNewswire
·
26 Feb

BRIEF-Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships

Reuters
·
19 Feb

Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

THOMSON REUTERS
·
19 Feb

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

GlobeNewswire
·
19 Feb

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

GlobeNewswire
·
18 Feb

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Sonnet BioTherapeutics appoints McAndrew as Chief Business Officer

TIPRANKS
·
13 Feb

BRIEF-Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer

Reuters
·
13 Feb

Sonnet Biotherapeutics Appoints Stephen Mcandrew, Ph.d. as Chief Business Officer

THOMSON REUTERS
·
13 Feb

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

GlobeNewswire
·
13 Feb

Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate

Benzinga
·
13 Feb